{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T17:40:36Z","timestamp":1787161236302,"version":"build-2736575974"},"reference-count":16,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,4,1]],"date-time":"2016-04-01T00:00:00Z","timestamp":1459468800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmaceutical and Biomedical Analysis"],"published-print":{"date-parts":[[2016,4]]},"DOI":"10.1016\/j.jpba.2016.01.030","type":"journal-article","created":{"date-parts":[[2016,1,16]],"date-time":"2016-01-16T11:30:48Z","timestamp":1452943848000},"page":"29-34","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"special_numbering":"C","title":["13C solid-state NMR analysis of the most common pharmaceutical excipients used in solid drug formulations Part II: CP kinetics and relaxation analysis"],"prefix":"10.1016","volume":"122","author":[{"given":"Dariusz Maciej","family":"Pisklak","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monika","family":"Zieli\u0144ska-Pisklak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u0141ukasz","family":"Szeleszczuk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iwona","family":"Wawer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jpba.2016.01.030_bib0005","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1016\/j.jpba.2014.07.011","article-title":"Solid-state NMR studies of theophylline co-crystals with dicarboxylic acids","volume":"100","author":"Pindelska","year":"2014","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.jpba.2016.01.030_bib0010","doi-asserted-by":"crossref","first-page":"2285","DOI":"10.1002\/jps.24490","article-title":"Crystal structures of tiotropium bromide and its monohydrate in view of combined solid-state NMR and GIPAW studies","volume":"104","author":"Pindelska","year":"2015","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.jpba.2016.01.030_bib0015","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1002\/jps.24249","article-title":"Solid-state NMR as an effective method of polymorphic analysis: solid dosage forms of clopidogrel hydrogensulfate","volume":"104","author":"Pindelska","year":"2015","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.jpba.2016.01.030_bib0020","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.jpba.2013.11.011","article-title":"Low level drug product API form analysis\u2014avalide tablet NIR quantitative method development and robustness challenges","volume":"89","author":"Pan","year":"2014","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.jpba.2016.01.030_bib0025","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.ijpharm.2010.04.017","article-title":"Quantitation of a polymorphic mixture of an active pharmaceutical ingredient with solid state 13C CPMAS NMR spectroscopy","volume":"394","author":"Virtanen","year":"2010","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jpba.2016.01.030_bib0030","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1002\/jps.23062","article-title":"Application of 13C CPMAS NMR for qualitative and quantitative characterization of carvedilol and its commercial formulations","volume":"101","author":"Zieli\u0144ska-Pisklak","year":"2012","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.jpba.2016.01.030_bib0035","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/S0066-4103(05)58003-7","article-title":"How far can the sensitivity of NMR be increased?","volume":"1","author":"Fujiwara","year":"2006","journal-title":"Annu. Rep. NMR Spectrosc."},{"key":"10.1016\/j.jpba.2016.01.030_bib0040","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1023\/A:1018922407786","article-title":"Solid-state nuclear magnetic resonance (NMR) spectra of pharmaceutical dosage forms","volume":"10","author":"Saindon","year":"1993","journal-title":"Pharm. Res."},{"key":"10.1016\/j.jpba.2016.01.030_bib0045","doi-asserted-by":"crossref","first-page":"2324","DOI":"10.1021\/ja4092038","article-title":"Dynamic nuclear polarization enhanced NMR spectroscopy for pharmaceutical formulations","volume":"136","author":"Rossini","year":"2014","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.jpba.2016.01.030_bib0050","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.jpba.2013.06.031","article-title":"13C cross-polarization magic-angle spinning nuclear magnetic resonance analysis of the solid drug forms with low concentration of an active ingredient-propranolol case","volume":"93","author":"Pisklak","year":"2014","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.jpba.2016.01.030_bib0055","series-title":"NMR Spectroscopy in Pharmaceutical Analysis","author":"Holzgrabe","year":"2008"},{"key":"10.1016\/j.jpba.2016.01.030_bib0060","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1021\/cr000060n","article-title":"Kinetics of cross-polarization in solid-state NMR: a guide for chemists","volume":"102","author":"Kolodziejski","year":"2002","journal-title":"Chem. Rev."},{"key":"10.1016\/j.jpba.2016.01.030_bib0065","doi-asserted-by":"crossref","first-page":"6951","DOI":"10.1063\/1.470372","article-title":"Heteronuclear decoupling in rotating solids","volume":"103","author":"Bennett","year":"1995","journal-title":"J. Chem. Phys."},{"key":"10.1016\/j.jpba.2016.01.030_bib0070","unstructured":"KaleidaGraph computer program, version 3.5 for PC, Synergy Software, 2000."},{"key":"10.1016\/j.jpba.2016.01.030_bib0075","series-title":"Polymeric Dispersions: Principles and Applications","first-page":"204","author":"Asua","year":"2012"},{"key":"10.1016\/j.jpba.2016.01.030_bib0080","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.ijpharm.2006.10.026","article-title":"Lactose: a definitive guide to polymorph determination","volume":"334","author":"Kirk","year":"2007","journal-title":"Int. J. Pharm."}],"container-title":["Journal of Pharmaceutical and Biomedical Analysis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0731708516300309?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0731708516300309?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,16]],"date-time":"2018-09-16T00:50:35Z","timestamp":1537059035000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0731708516300309"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,4]]},"references-count":16,"alternative-id":["S0731708516300309"],"URL":"https:\/\/doi.org\/10.1016\/j.jpba.2016.01.030","relation":{},"ISSN":["0731-7085"],"issn-type":[{"value":"0731-7085","type":"print"}],"subject":[],"published":{"date-parts":[[2016,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"13C solid-state NMR analysis of the most common pharmaceutical excipients used in solid drug formulations Part II: CP kinetics and relaxation analysis","name":"articletitle","label":"Article Title"},{"value":"Journal of Pharmaceutical and Biomedical Analysis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jpba.2016.01.030","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2016 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}